PDCD1 and B-cell chronic lymphocytic leukemia: Mechanistically, upon ibrutinib treatment, the downregulation of programmed cell death ligand 1 (PD-L1) on CLL cells and of programmed cell death protein 1 (PD-1) on T cells is observed, potentially reverting pseudo-exhaustion and enhancing antitumor immune responses [17].